New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export LLY’s income statement to Excel — free account
Eli Lilly and Company
LLYHealthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
1,352.05
0.40
+0.03%
Follow LLY
Alert me
Revenue to profit Twelve months to Sep 30, 2026
Of every $100 of revenue, $31.90 was left as profit. Gross margin has risen two quarters running, from 82.8% to 83.6%. What is an income statement?
| Revenue | 86.5 | 100.0% |
|---|---|---|
| Cost of revenue | −14.1 | −16.4% |
| Gross profit | 72.3 | 83.6% |
| Research & development | −15.4 | −17.8% |
| Selling, general & admin | −12.6 | −14.6% |
| Other operating costs | −9.5 | −11.0% |
| Operating income | 34.8 | 40.3% |
| Income tax | −7.2 | −8.3% |
| Net income | 27.6 | 31.9% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $65.2B | $72.2B | $79.7B | $86.5B |
| Operating income | $26.3B | $31.5B | $33.6B | $34.8B |
| Net income | $20.6B | $25.3B | $26.7B | $27.6B |
| Net margin (right axis) | 31.7% | 35.0% | 33.5% | 31.9% |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
86,461.00 | 79,665.00 | 72,249.00 | 65,179.00 |
+8 more TTM periods Free account |
Cost of Revenue |
14,149.00 | 13,224.00 | 12,404.00 | 11,052.00 | |
Gross Profit |
72,312.00 | 66,441.00 | 59,845.00 | 54,127.00 | |
R&D Expenses |
15,377.00 | 14,596.00 | 14,113.00 | 13,337.00 | |
SG&A Expenses |
12,621.00 | 12,237.00 | 11,560.00 | 11,094.00 | |
Operating Income |
34,814.00 | 33,633.00 | 31,522.00 | 26,302.00 | |
Non-operating Income/Expense |
(46.00) | (38.00) | (397.00) | (571.00) | |
Non-operating Interest Expenses |
— | 403.00 | — | — | |
| 34,768.00 | 33,595.00 | 31,125.00 | 25,731.00 | ||
Income Tax Provision |
7,189.00 | 6,884.00 | 5,848.00 | 5,091.00 | |
Income after Tax |
27,579.00 | 26,711.00 | 25,277.00 | 20,640.00 | |
Net Income Common |
27,579.00 | 26,711.00 | 25,277.00 | 20,640.00 | |
EPS (Basic) |
30.81 | 29.80 | 28.15 | 22.95 | |
EPS (Diluted) |
30.81 | 29.80 | 28.15 | 22.95 | |
Shares (Basic, Weighted) |
894.03 | 895.28 | 896.65 | 897.70 | |
Shares (Diluted, Weighted) |
895.58 | 896.93 | 898.45 | 899.63 | |
Gross Margin |
83.64% | 83.40% | 82.83% | 83.04% | |
EBIT Margin |
40.27% | 42.22% | 43.63% | 40.35% | |
EBT margin |
40.21% | 42.17% | 43.08% | 39.48% | |
Net Profit Margin |
31.90% | 33.53% | 34.99% | 31.67% | |
Free Cash Flow Margin |
22.74% | 22.83% | 16.36% | 13.77% | |
EBITDA |
36,988.00 | 35,732.00 | 33,565.00 | 28,299.00 | |
EBIT |
34,814.00 | 33,633.00 | 31,522.00 | 26,302.00 | |
EPS (Diluted, from Cont. Ops) |
30.80 | 29.79 | 28.14 | 22.95 | |
EPS (Diluted, Consolidated) |
30.80 | 29.79 | 28.14 | 22.95 | |
EPS (Basic, Consolidated) |
30.85 | 29.85 | 28.20 | 23.00 | |
Shares (Diluted, Average) |
895.26 | 896.60 | 898.13 | 899.30 | |
EPS (Basic, from Continuous Ops) |
30.85 | 29.85 | 28.20 | 23.00 | |
Income from Continuous Operations |
27,579.00 | 26,711.00 | 25,277.00 | 20,640.00 | |
Consolidated Net Income/Loss |
27,579.00 | 26,711.00 | 25,277.00 | 20,640.00 | |
EBITDA Margin |
42.78% | 44.85% | 46.46% | 43.42% | |
Operating Cash Flow Margin |
35.44% | 35.25% | 28.35% | 25.80% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026